Intra-operative Magnesium Sulphate for Post-operative Pain in Patients Undergoing Total Abdominal Hysterectomy Under General Anesthesia
Intra-operative Magnesium Sulphate for Post-operative Pain in Patients Undergoing Total Abdominal Hysterectomy Under General Anesthesia
Post-operative pain management is a complex entity. It is one of the most critical parameters in the enhanced recovery after surgery protocol. Adequate postoperative pain relief leads to earlier mobilisation, shortened hospital stay, reduced hospital costs and increased patient satisfaction.
For post-operative analgesia, opioids have long been the mainstay of drugs used; however, they produce unwanted side effects, such as respiratory depression, nausea, vomiting and dependence. The major goal in postoperative pain management is to minimise the dose of a single medication and lessen its side effects, while still providing adequate analgesia by the use of multimodal analgesia. Paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), regional techniques like epidural analgesia, different kind of blocks and local wound infiltration are some of the components of multimodal approach to post- operative analgesia.
Besides, there are some drugs that may be used as adjuvants to opioids to enhance the analgesic efficacy and facilitate opioid sparing with a reduction in opioid related side effects. Magnesium sulphate, due to its N- Methyl D- Aspartate (NMDA) blocking property, has been studied as one of such non opioid adjuvants. The outcome of many of these studies is in favour of magnesium sulphate but there are negative reports as well.
So, in this study the investigators aim to evaluate the efficacy of intra-operative intravenous magnesium sulphate for post-operative pain and opioid use in patients undergoing abdominal hysterectomy under general anaesthesia.
All women who have been planned for total abdominal hysterectomy will be enrolled in the study. Patients who do not meet the inclusion criteria or those who refuse to participate will be excluded from study . Other enrolled patients who meet the eligibility criteria will be randomised and allocated to two study groups- Magnesium (M) group and Control (C) group by computer generated numbers that will be concealed in a sequentially numbered, opaque sealed envelopes. The envelopes will be opened before the surgery begins by a doctor not involved in the study and not assigned to the Gynaecology operating room. The drug will be prepared and labelled study drug as: In group M- Magnesium sulphate @ 50mg/ kg in 100 ml of normal saline and in group C- 100 ml of normal saline. Anaesthetic management, administration of the study drug and any intra-operative changes in vitals requiring treatment will be recorded in the anaesthesia management sheet by another doctor who is assigned to Gynaecology operating room.
A day prior to surgery, eligible patients will be explained in detail about the purpose of study, need, benefits and risks of procedure. The participants will be explained about numerical rating scale (NRS) of pain, how to use it and rate it during post-operative period. Written informed consent will be obtained. The patients will be counselled about fasting protocol and asked to remain nil per oral of 2 hours for clear liquid, 6 hours for light foods and 8 hours for fatty food.
In pre-operative holding area : Baseline vitals systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP), heart rate (HR), respiratory rate (RR), Oxygen saturation (SpO2) will be recorded. Intravenous access will be established with an 18 or 20 gauge cannula. A 3-way stopcock will be attached to the cannula and Lactated Ringer's will be infused @ 100ml/hr.
In the operating room: Standard American Society of Anaesthesiologists monitors will be attached. All patients will be subjected to a standardised anaesthetic protocol. Induction of general anaesthesia, intubation, ventilation parameter set up and maintenance of anaesthesia will be done as per standard anaesthetic practice in our institute.
Meanwhile, at the time of induction, 100 ml of study drug will be infused via side port of 3-way stopcock over 20-30 minutes. Ringer lactate solution will be infused throughout the surgery as per standard practice in our institute. Hemodynamic parameters SBP, DBP, HR, SpO2, RR will be monitored and recorded as per anaesthesia protocol. Additional analgesia during the peri-operative period will be standardised with IV Paracetamol 15 mg/kg post induction and IV Fentanyl 0.5 mcg/kg every hour of intra-operative period and any additional dosing of analgesia will be recorded. Urine output monitoring will be done on hourly basis. If less than 0.5 ml/kg/hr, underlying cause will be looked for, and if no other causes is found, Mg toxicity will be suspected and serum magnesium level will be sent. Meanwhile necessary medical management will be done. Post operative nausea and vomiting (PONV) prophylaxis will be standardised in both groups of patient. IV Ondansetron 4mg single dose 15 to 20 minutes before extubation will be given. 0.25% Bupivacaine not exceeding 2 mg/kg dose will be administered locally at the site of surgical incision at the end of surgery. Reversal of muscle relaxation and extubation will be done as per attending anaesthesiologist. Patient will be transferred to recovery room.
Post operatively: Patients will be held in recovery room until adequate recovery from anaesthesia as judged by the Modified Aldrete Score. Score ≥ 9 will be deemed adequate. Post operative pain assessment will be done with Numerical Rating Scale (NRS). The NRS is a pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable". Pain assessment will be done by the attending nurse at time 0, 1, 6, 12, 18, 24 hours. The time 0 will be the first assessment of pain done in the recovery room once the patient is fully awake. If NRS > 3 at any time within 24 hours, IV Tramadol 50 mg will be given as rescue analgesia. NRS and vitals at this point will be recorded. If NRS > 3 even after 10 minutes of rescue analgesic , second dose of 50 mg of IV Tramadol up to a total dose of 150 mg including the initial bolus will be given.Vitals SBP, DBP, MAP, HR, RR, SpO2 will be monitored and recorded at 0, 1, 6, 12, 18, 24 hours. 24 hours total opioid consumption post-operatively will be recorded. Side effects of magnesium sulphate including nausea/ vomiting, flushing, hypotension, bradycardia, blurring of vision, decreased respiratory rate , muscle weakness, loss of deep tendon reflexes will be recorded and managed as per protocol.
Maintenance analgesia will be standardised as : IV Paracetamol 15 mg/kg every 6 hours and IV Ketorolac 30mg every 8 hours. For postoperative nausea and vomiting, IV Ondansetron 4 mg will be given every 8 hours as standard practice.
Management of the patients for any side effects will be done as described below:
Hypotension with SBP < 90 mmHg will be managed with IV Mephentermine 6mg bolus and repeated as required.
Bradycardia with HR < 50 beats/min will be managed with IV Atropine 0.6 mg bolus.
Respiratory depression will be graded as mild (RR 10-12), moderate (RR 8-10) and severe ( RR <8). Oxygen @ 6 L/ minute will supplemented via face mask. In case of severe respiratory depression, serum magnesium level will be sent in suspicion magnesium toxicity. If magnesium level comes out to be normal, respiratory depression due to opioid will be suspected and IV naloxone 0.4 mg will be given and repeated 2-3 minutes until RR rises above 8. Total naloxone dose will not exceed 10 mg.
Sedation will be quantified according to Pasero Opioid-induced Sedation Scale ( POSS) . In case of POSS >3, IV Naloxone will be infused as mentioned earlier.
If milder signs of hypermagnesemia like nausea, dizziness, confusion is noticed, it will be recorded and informed to the principal investigator. Meanwhile serum Magnesium level will be sent. The principal investigator will then attend the patient for signs of moderate hypermagnesemia and manage accordingly. Patients with normal renal function clinically assessed as urine output >0.5ml/kg/hour and mild hypermagnesemia will require no treatment. If signs of moderate hypermagnesemia occur, the principal investigator will attend the case for close monitoring of the ECG, blood pressure, neuromuscular function and respiratory function. If either hyporeflexia assessed as loss of patellar reflex, respiratory depression or changes in ECG is noticed individually or all at once, IV normal saline at 150 ml/hour and IV calcium gluconate 1 gm over 5 minutes will be infused. The rationale is that the actions of magnesium in neuromuscular and cardiac function become antagonized by calcium. In absence of improvement, same dose will be repeated. In case of severe hypermagnesemia, intravenous loop diuretic, IV Furosemide 1 mg/kg will be given to increase renal magnesium excretion.
Inclusion Criteria:
Exclusion Criteria: